Title:
A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma.
Phase:
III
Contact:
Martina Gronkowski / Kontaktperson
Email-Address:
Martina.Gronkowski@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. Gerlinde Egerer
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT04650984
EudraCT-Number:
Siehe EU klinisches Studienregister
2016-003239-38